TARSUS PHARMACEUTICALS INC's ticker is TARS and the CUSIP is 87650L103. A total of 75 filers reported holding TARSUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 4.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,620,200 | -1.7% | 260,000 | 0.0% | 1.37% | -1.7% |
| Q2 2023 | $4,698,200 | +43.8% | 260,000 | 0.0% | 1.39% | +72.0% |
| Q1 2023 | $3,268,200 | +85634.5% | 260,000 | 0.0% | 0.81% | -22.6% |
| Q4 2022 | $3,812 | -99.9% | 260,000 | 0.0% | 1.04% | -19.3% |
| Q3 2022 | $4,451,000 | +17.3% | 260,000 | 0.0% | 1.29% | +24.2% |
| Q2 2022 | $3,796,000 | -13.2% | 260,000 | 0.0% | 1.04% | +14.0% |
| Q1 2022 | $4,373,000 | -25.2% | 260,000 | 0.0% | 0.91% | +5.4% |
| Q4 2021 | $5,850,000 | +4.4% | 260,000 | 0.0% | 0.87% | +2.6% |
| Q3 2021 | $5,603,000 | – | 260,000 | – | 0.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 2,084,370 | $30,432,000 | 4.62% |
| Vivo Capital, LLC | 2,312,368 | $33,761,000 | 3.39% |
| Frazier Life Sciences Management, L.P. | 1,787,527 | $26,098,000 | 2.46% |
| Cormorant Asset Management, LP | 1,875,000 | $27,375,000 | 2.07% |
| Sands Capital Ventures, LLC | 260,000 | $3,796,000 | 1.04% |
| Ghost Tree Capital, LLC | 120,000 | $1,752,000 | 0.91% |
| RTW INVESTMENTS, LP | 2,013,601 | $29,399,000 | 0.76% |
| COWEN AND COMPANY, LLC | 534,524 | $7,804,000 | 0.75% |
| Perceptive Advisors | 1,296,416 | $18,927,000 | 0.59% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,324,214 | $19,334,000 | 0.40% |